Table 1.
Cmpd | LGFE (kcal/mol) | IC50c (μM) | Viabilityc,d (μM) | Selective Index (viability/IC50) |
---|---|---|---|---|
DFB | −24.7 | 136 | 500 | 3.68 |
1a | −33.08 | 210 | 1000 | 4.76 |
1b | −31.22 | 160 | 1000 | 24.6 |
1c | −32.75 | 180 | 1000 | 5.68 |
1d | −34.24 | 46 | 1000 | 21.8 |
1e | −29.17 | 46 | 300 | 6.49 |
1f | −30.09 | 21 | 300 | 14.6 |
2b | −33.73 | 58 | 1000 | 17.4 |
2c | −33.43 | 71 | 1000 | 14.1 |
2d | −32.04 | 230 | 1000 | 4.37 |
2f | −29.76 | 67 | 400 | 5.96 |
3a | −33.08 | 30 | 1000 | 33.0 |
3b | −33.79 | 200 | 1000 | 5.03 |
3c | −33.28 | 130 | 400 | 3.01 |
3d | −29.83 | 200 | 200 | 1.02 |
3e | −32.03 | 170 | 800 | 4.60 |
The listed result was the average of three independent experiments.
The highest concentration of the tested compound at which no obvious cytotoxicity was observed.